Expert Review of Gastroenterology & Hepatology最新文献_第3页

Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-02-05 DOI: 10.1080/17474124.2025.2461516

Albert J Bredenoord, Evan S Dellon, Christoph Schlag, Antonella Cianferoni, Changming Xia, Tiffany Pela, Sandy Durrani, Amr Radwan, Juby A Jacob-Nara

{"title":"Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.","authors":"Albert J Bredenoord, Evan S Dellon, Christoph Schlag, Antonella Cianferoni, Changming Xia, Tiffany Pela, Sandy Durrani, Amr Radwan, Juby A Jacob-Nara","doi":"10.1080/17474124.2025.2461516","DOIUrl":"10.1080/17474124.2025.2461516","url":null,"abstract":"Background: Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly is approved for the treatment of EoE in patients ≥ 1 year old, weighing ≥ 15 kg. This analysis aimed to evaluate dupilumab efficacy in patients from the LIBERTY EoE TREET trial (NCT03633617), with prior history of different EoE interventions.Research design and methods: This analysis included patients from Parts B/B - C of LIBERTY EoE TREET. Dupilumab efficacy was analyzed according to prior swallowed budesonide or fluticasone use and in those patients with previously trialed food elimination diet, esophageal dilation, or baseline proton pump inhibitor use, as stratified by prior swallowed topical corticosteroid (STC) use or STC inadequate response/intolerance/contraindication.Results: Dupilumab improved the proportion of patients achieving peak intraepithelial eosinophil count ≤ 6 eosinophils/high-power field, absolute change in Dysphagia Symptom Questionnaire score, and other histologic, symptomatic, and endoscopic endpoints vs. placebo at Week (W) 24, irrespective of prior swallowed budesonide/fluticasone use. Improvements were maintained at W52. Similar results were observed across the other subgroups.Conclusion: Dupilumab was efficacious in patients with EoE irrespective of prior treatments/interventions.Clinical trial registration: www.clinicaltrials.gov identifier is NCT03633617.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"197-209"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing liver fibrosis research: the promise of 3D organoid models in understanding and treating chronic liver disease. 革命性的肝纤维化研究：三维类器官模型在理解和治疗慢性肝病方面的前景。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-20 DOI: 10.1080/17474124.2025.2455581

Umashanker Navik, Sumeet Kumar Singh, Amit Khurana, Ralf Weiskirchen

{"title":"Revolutionizing liver fibrosis research: the promise of 3D organoid models in understanding and treating chronic liver disease.","authors":"Umashanker Navik, Sumeet Kumar Singh, Amit Khurana, Ralf Weiskirchen","doi":"10.1080/17474124.2025.2455581","DOIUrl":"10.1080/17474124.2025.2455581","url":null,"abstract":"Introduction: Liver fibrosis, marked by excessive extracellular matrix deposition, is a significant consequence of chronic liver injuries from various conditions. It can progress to end-stage liver disease, with liver transplantation often being the only treatment option. Recent advancements in 3D-organoid technology have transformed liver disease research by providing models that mimic the human liver's physiological environment, offering insights into mechanisms of fibrosis and potential therapies.Areas covered: This report highlights cellular and molecular factors leading to liver fibrosis and the limitations of 2D in vitro models in replicating complex liver dynamics. It emphasizes the advantages of 3D-liver organoids as promising tools for advancing research and drug discovery, providing greater accuracy than traditional models. Additionally, it discusses recent advancements in the development and future applications of liver organoids in fibrosis research.Expert opinion: Liver organoids currently lack cellular diversity and essential features such as vascular, neuronal, microbiome, and immune responses, limiting their effectiveness in mature fibrosis models. Addressing these shortcomings through bioengineering advancements and emerging technologies like CRISPR/Cas9 will enhance the utility of liver organoids.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"105-110"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are bowel purgatives useful in small bowel capsule endoscopy? 肠泻药在小肠胶囊内镜检查中有用吗？

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-23 DOI: 10.1080/17474124.2025.2458168

Naoki Hosoe

引用次数: 0

Antibiotics in decompensated liver disease - who, when and for how long?

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-02-20 DOI: 10.1080/17474124.2025.2464044

Frederic Haedge, Tony Bruns

{"title":"Antibiotics in decompensated liver disease - who, when and for how long?","authors":"Frederic Haedge, Tony Bruns","doi":"10.1080/17474124.2025.2464044","DOIUrl":"10.1080/17474124.2025.2464044","url":null,"abstract":"Introduction: Bacterial infections are a leading cause of hospitalization and mortality in patients with decompensated cirrhosis. Antibiotic prophylaxis in cirrhotic patients has demonstrated significant short-term reductions in bacterial infections in randomized controlled trials, but at the cost of drug resistance and with uncertain survival benefits.Areas covered: This review examines antibiotic use in cirrhosis, focusing on patients most likely to benefit from antibiotic prophylaxis, management strategies for infections through risk-based antibiotic selection and timely treatment initiation, challenges posed by the emergence of multidrug-resistant organisms, and principles of antimicrobial stewardship.Expert opinion: The efficacy of prophylaxis has decreased over time, and current registry data have questioned its use, emphasizing the need for better risk-based individualized strategies. When bacterial infections occur, the efficacy of antimicrobial therapies depends heavily on local epidemiological patterns and individual patient risk factors, necessitating tailored antibiotic selection based on regional resistance data and specific clinical scenarios. Nosocomial infections, colonization with multidrug-resistant organisms, and prior exposure to systemic antibiotics are key risk factors that should guide empirical therapy selection. Until evidence-based algorithms are available, clinicians should continue to adopt individualized approaches, guided by available evidence, local specificities, and antimicrobial stewardship principles to optimize patient outcomes.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"111-130"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute severe ulcerative colitis: defining the precise moment for colectomy. 急性严重溃疡性结肠炎：确定结肠切除术的精确时机。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1080/17474124.2024.2448451

Paulo Gustavo Kotze, Sailish Honap, Mariane Christina Savio, Rafaela Molteni Moretti Araújo, Abel Botelho Quaresma, Laurent Peyrin-Biroulet

{"title":"Acute severe ulcerative colitis: defining the precise moment for colectomy.","authors":"Paulo Gustavo Kotze, Sailish Honap, Mariane Christina Savio, Rafaela Molteni Moretti Araújo, Abel Botelho Quaresma, Laurent Peyrin-Biroulet","doi":"10.1080/17474124.2024.2448451","DOIUrl":"10.1080/17474124.2024.2448451","url":null,"abstract":"Introduction: Acute severe ulcerative colitis (ASUC) is a critical manifestation of ulcerative colitis (UC), often necessitating colectomy when medical management fails. Despite advancements in therapeutic interventions such as corticosteroids, biologics, and JAK inhibitors, a significant proportion of patients require surgery, with colectomy rates ranging from 10% to 15%.Areas covered: This paper reviews the factors influencing the timing and necessity of colectomy in ASUC management, emphasizing the importance of multidisciplinary decision-making involving gastroenterologists and surgeons.Expert opinion: Key surgical indications include failure of medical therapy, toxic megacolon, perforation, uncontrolled bleeding, and systemic deterioration. Delays in surgery can result in higher morbidity and mortality rates, making timely intervention essential. This review highlights surgical techniques, including total colectomy and end ileostomy, and discusses potential complications, urging a balanced approach to optimize patient outcomes.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"5-14"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modulating the microbiome in chronic liver diseases - current evidence on the role of fecal microbiota transplantation. 调节慢性肝病中的微生物群——粪便微生物群移植作用的最新证据。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-16 DOI: 10.1080/17474124.2025.2450707

Srishti Saha, Bernd Schnabl

{"title":"Modulating the microbiome in chronic liver diseases - current evidence on the role of fecal microbiota transplantation.","authors":"Srishti Saha, Bernd Schnabl","doi":"10.1080/17474124.2025.2450707","DOIUrl":"10.1080/17474124.2025.2450707","url":null,"abstract":"Introduction: The gut microbiota has a complex relationship with the human host and is key to maintaining health. Disruption of the healthy diverse gut microbial milieu plays an important role in the pathogenesis of several diseases including Clostridioides difficile infection (CDI), inflammatory bowel disease, irritable bowel syndrome, alcohol-related liver disease and metabolic-dysfunction associated steatotic liver disease (MASLD). Fecal microbiota transplantation (FMT) is highly effective in treating CDI, though its utility in other diseases is still being explored.Areas covered: In this narrative review, we explore the role of gut microbiota in liver diseases, focusing on key changes in the microbial composition and function. We summarize current evidence on the role of FMT, identifying gaps in current research and outlining future directions for investigation. We comprehensively searched PubMed through 15 October 2024 to identify relevant studies.Expert opinion: While data from available studies shows promise, more research is necessary before we can use FMT for liver diseases. Key areas that require further study are - determining the optimal FMT regimen for each disease, establishing efficacy and safety with larger clinical trials, ensuring safe and equitable access to the FMT product and mechanistic insights into the reasons for success or failure of FMT.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"53-64"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PSC patient with jaundice - should we ERCP? 伴有黄疸的PSC患者-是否应该进行ERCP？

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-08 DOI: 10.1080/17474124.2025.2450723

Muhammad Umair Tayyub, Deepak Joshi

引用次数: 0

Serological testing for celiac disease in children.

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-02-04 DOI: 10.1080/17474124.2025.2462245

Marleena Repo, Sara Koskimaa, Saana Paavola, Kalle Kurppa

{"title":"Serological testing for celiac disease in children.","authors":"Marleena Repo, Sara Koskimaa, Saana Paavola, Kalle Kurppa","doi":"10.1080/17474124.2025.2462245","DOIUrl":"10.1080/17474124.2025.2462245","url":null,"abstract":"Introduction: Celiac disease is one of the most common chronic immune-mediated gastrointestinal conditions, characterized by the presence of disease-specific serum antibodies against self-antigen transglutaminase 2. Even though modern serological assays can identify most untreated celiac disease patients and are also increasingly being used to establish a diagnosis, several challenges are associated with the tests, including a lack of standardization, the variable sensitivity and specificity of commercial assays, and inadequate sensitivity for monitoring adherence to a gluten-free diet.Areas covered: This narrative review outlines the current use of serological tests in case-finding and screening, as well as in the follow-up of dietary treatment. Additionally, the possible challenges and pitfalls of serological tests, along with future directions, are addressed.Expert opinion: The excellent accuracy of modern autoantibody tests, especially for greatly elevated levels of transglutaminase 2 antibodies and positive endomysial antibodies, enables using serological testing in establishing a diagnosis. However, better international standardization of the assays is required, the necessity of endomysial antibody testing needs to be further scrutinized, and additional research is needed to improve noninvasive tools for follow-up and to further expand the no-biopsy criteria for celiac disease.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"155-164"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis. 无创生物标志物在监测晚期肝纤维化细胞损伤中的作用。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-09 DOI: 10.1080/17474124.2025.2450717

Riccardo Righetti, Felice Cinque, Keyur Patel, Giada Sebastiani

{"title":"The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis.","authors":"Riccardo Righetti, Felice Cinque, Keyur Patel, Giada Sebastiani","doi":"10.1080/17474124.2025.2450717","DOIUrl":"10.1080/17474124.2025.2450717","url":null,"abstract":"Introduction: Accurate and reliable diagnosis and monitoring of hepatic fibrosis is increasingly important given the variable natural history in chronic liver disease (CLD) and expanding antifibrotic therapeutic options targeting reversibility of early-stage cirrhosis. This highlights the need to develop more refined and effective noninvasive techniques for the dynamic assessment of fibrogenesis and fibrolysis.Areas covered: We conducted a literature review on PubMed, from 1 December 1970, to 1 November 2024, to evaluate and compare available blood-based and imaging-based noninvasive tools for hepatic fibrosis diagnosis and monitoring. Simple scores such as FIB-4 and NAFLD fibrosis score are suitable for excluding significant or advanced fibrosis, while tertiary centers should adopt complex scores and liver stiffness measurement as part of a secondary diagnostic and more comprehensive evaluation. Moreover, the advent of multiomics for high-resolution molecular profiling, and integration of artificial intelligence for noninvasive diagnostics holds promise for revolutionizing fibrosis monitoring and treatment through novel biomarker discovery and predictive omics-based algorithms.Expert opinion: The increased shift toward noninvasive diagnostics for liver fibrosis needs to align with personalized medicine, enabling more effective, tailored management strategies for patients with liver disease in the future.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"65-80"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The TL1A inhibitors in IBD: what's in the pot? TL1A抑制剂在IBD中的作用是什么？

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2025-01-01 Epub Date: 2025-01-08 DOI: 10.1080/17474124.2025.2450795

F Lusetti, C Bezzio, A De Bernardi, M Dota, G Manes, S Saibeni

{"title":"The TL1A inhibitors in IBD: what's in the pot?","authors":"F Lusetti, C Bezzio, A De Bernardi, M Dota, G Manes, S Saibeni","doi":"10.1080/17474124.2025.2450795","DOIUrl":"10.1080/17474124.2025.2450795","url":null,"abstract":"Introduction: Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), present ongoing challenges despite advances in pathophysiological understanding and therapeutic options. Current therapies often fail to achieve sustained remission, necessitating exploration of novel treatment targets.Areas covered: This review explores the role of Tumor Necrosis Factor-like cytokine 1A (TL1A) and its receptor DR3 in IBD pathogenesis, detailing their involvement in mucosal homeostasis and immune modulation. Recent studies on TL1A inhibitors highlight their potential in mitigating inflammation and fibrosis in IBD.Expert opinion: TL1A inhibition emerges as a promising therapeutic strategy, supported by encouraging outcomes in clinical trials for moderate to severe IBD. Future research may elucidate TL1A's broader impact on immunity, epithelial integrity and fibrosis, offering new avenues for therapeutic intervention and biomarker discovery. Ongoing phase 3 trials are pivotal in assessing TL1A inhibitors as effective and safe treatments for IBD. Additionally, exploration of TL1A's role in fibrosis-associated complications and its potential as a biomarker for treatment response holds promise for personalized medicine approaches. Consideration of TL1A inhibition in concurrent immune-mediated inflammatory diseases suggests broader therapeutic implications beyond gastrointestinal manifestations of IBD.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"15-25"},"PeriodicalIF":3.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0